CLINICAL TRIAL

The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: ClinicalTrials.gov
Date: 2026-05-08
Source: ClinicalTrials.gov
DOI: Unavailable
PubMed: Unavailable

Authors

University Medical Center Groningen

Watch author

Derived topics and classifications

psilocybin Depression Anxiety End-of-Life Distress Chronic Pain Brain Imaging Biomarkers Spirituality Clinical Trial Safety Adverse Events Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Psychedelics and Psychedelic-Assisted Psychotherapy.The American journal of psychiatry · 2020-05-01 An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in LifeClinicalTrials.gov · 2026-08-17 Psychedelics and Psychedelic-Assisted Psychotherapy.Focus (American Psychiatric Publishing) · 2021-01-01